Gabriele Varano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gabriele Varano has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
- Stefano Casola
Genetics of B Cells and Lymphoma Unit, IFOM ETS-The AIRC Institute of Molecular Oncology, Milano, Italy
57 shared publications - Euplio Visco
18Hematopathology Diagnostic Area, Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
48 shared publications - Luisa Lorenzi
Pathology Unit, ASST Spedali Civili di Brescia University of Brescia Brescia Italy
28 shared publications - Maurilio Ponzoni
Pathology Unit IRCCS San Raffaele Scientific Institute Milan Italy
28 shared publications - Paola Sindaco
Genetics of B Cells and Lymphoma Unit, IFOM ETS-The AIRC Institute of Molecular Oncology, Milano, Italy
28 shared publications - Silvia Lonardi
Pathology Section, Department of Molecular and Translational Medicine, University of Brescia and Pathology Unit, ASST Spedali Civili di Brescia, Brescia, Italy
28 shared publications
Latest Publications
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from The B-cell Receptor Blueprint in Lymphoma: Mechanisms and Therapeutic Opportunities
Figure S1. Flow cytometry gating strategy for assessment of surface BCR expression in normal and malignant B cell subsets.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from The B-cell Receptor Blueprint in Lymphoma: Mechanisms and Therapeutic Opportunities
Figure S1. Flow cytometry gating strategy for assessment of surface BCR expression in normal and malignant B cell subsets.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from The B-cell Receptor Blueprint in Lymphoma: Mechanisms and Therapeutic Opportunities
List of antibody sources for immunohistochemical and flow cytometric analyses displayed in Figures 1 and 2
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from The B-cell Receptor Blueprint in Lymphoma: Mechanisms and Therapeutic Opportunities
List of antibody sources for immunohistochemical and flow cytometric analyses displayed in Figures 1 and 2
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Data from The B-cell Receptor Blueprint in Lymphoma: Mechanisms and Therapeutic Opportunities
The B-cell receptor (BCR) is central to normal and malignant B-cell biology, integrating intrinsic programs with microenvironmental cues to shape cell fate. Across mature B-cell lymphomas, differences in BCR expression, class, and signaling mode define distinct pathogenetic routes and therapeutic vulnerabilities, ranging from BCR-dependent to BCR-silent states. We propose a BCR blueprint that positions these tumors along a continuum of signaling modes and class-imposed functions, emphasizing germinal center–derived lymphomas. This framework links specific BCR states to genetic lesions and microenvironmental niches, underscoring the value of routinely monitoring BCR features to track tumor evolution and inform therapy.Significance:B-cell lymphomas exploit diverse BCR expression levels, classes, and signaling modes that span BCR-addicted to BCR-silent states and shape their genetic programs and therapeutic dependencies. A unified BCR blueprint reframes these diseases along a continuum of BCR signaling and isotype-driven biology, particularly in germinal center–derived entities. Embedding this blueprint into routine clinical testing has the potential to improve prediction of response or resistance to BCR-targeted and other mechanism–based therapies.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from The B-cell Receptor Blueprint in Lymphoma: Mechanisms and Therapeutic Opportunities
The B-cell receptor (BCR) is central to normal and malignant B-cell biology, integrating intrinsic programs with microenvironmental cues to shape cell fate. Across mature B-cell lymphomas, differences in BCR expression, class, and signaling mode define distinct pathogenetic routes and therapeutic vulnerabilities, ranging from BCR-dependent to BCR-silent states. We propose a BCR blueprint that positions these tumors along a continuum of signaling modes and class-imposed functions, emphasizing germinal center–derived lymphomas. This framework links specific BCR states to genetic lesions and microenvironmental niches, underscoring the value of routinely monitoring BCR features to track tumor evolution and inform therapy.Significance:B-cell lymphomas exploit diverse BCR expression levels, classes, and signaling modes that span BCR-addicted to BCR-silent states and shape their genetic programs and therapeutic dependencies. A unified BCR blueprint reframes these diseases along a continuum of BCR signaling and isotype-driven biology, particularly in germinal center–derived entities. Embedding this blueprint into routine clinical testing has the potential to improve prediction of response or resistance to BCR-targeted and other mechanism–based therapies.
- 6 March 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (6) , 1306-1310
RAG1/2 expression in IGH-switched follicular lymphoma associated with transformation to high-grade B-cell lymphoma
- 6 March 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (6) , 1306-1310
RAG1/2 expression in IGH-switched follicular lymphoma associated with transformation to high-grade B-cell lymphoma
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (3) , 380-393
The B-cell Receptor Blueprint in Lymphoma: Mechanisms and Therapeutic Opportunities
The B-cell receptor (BCR) is central to normal and malignant B-cell biology, integrating intrinsic programs with microenvironmental cues to shape cell fate. Across mature B-cell lymphomas, differences in BCR expression, class, and signaling mode define distinct pathogenetic routes and therapeutic vulnerabilities, ranging from BCR-dependent to BCR-silent states. We propose a BCR blueprint that positions these tumors along a continuum of signaling modes and class-imposed functions, emphasizing germinal center–derived lymphomas. This framework links specific BCR states to genetic lesions and microenvironmental niches, underscoring the value of routinely monitoring BCR features to track tumor evolution and inform therapy. Significance: B-cell lymphomas exploit diverse BCR expression levels, classes, and signaling modes that span BCR-addicted to BCR-silent states and shape their genetic programs and therapeutic dependencies. A unified BCR blueprint reframes these diseases along a continuum of BCR signaling and isotype-driven biology, particularly in germinal center–derived entities. Embedding this blueprint into routine clinical testing has the potential to improve prediction of response or resistance to BCR-targeted and other mechanism–based therapies.
- 2 March 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (3) , 380-393
Open AccessThe B-cell Receptor Blueprint in Lymphoma: Mechanisms and Therapeutic Opportunities
The B-cell receptor (BCR) is central to normal and malignant B-cell biology, integrating intrinsic programs with microenvironmental cues to shape cell fate. Across mature B-cell lymphomas, differences in BCR expression, class, and signaling mode define distinct pathogenetic routes and therapeutic vulnerabilities, ranging from BCR-dependent to BCR-silent states. We propose a BCR blueprint that positions these tumors along a continuum of signaling modes and class-imposed functions, emphasizing germinal center–derived lymphomas. This framework links specific BCR states to genetic lesions and microenvironmental niches, underscoring the value of routinely monitoring BCR features to track tumor evolution and inform therapy. Significance: B-cell lymphomas exploit diverse BCR expression levels, classes, and signaling modes that span BCR-addicted to BCR-silent states and shape their genetic programs and therapeutic dependencies. A unified BCR blueprint reframes these diseases along a continuum of BCR signaling and isotype-driven biology, particularly in germinal center–derived entities. Embedding this blueprint into routine clinical testing has the potential to improve prediction of response or resistance to BCR-targeted and other mechanism–based therapies.
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
IGH and CD79B expression and interaction in HGBCL-DH-BCL2(-BCL6), and relation to follicular lymphoma.
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
IGH and CD79B expression and interaction in HGBCL-DH-BCL2(-BCL6), and relation to follicular lymphoma.
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Configuration of IGH, MYC and BCL2 loci in HGBCL-DH-BCL2(-BCL6) and RAG1/2 involvement in t(8;22).
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Configuration of IGH, MYC and BCL2 loci in HGBCL-DH-BCL2(-BCL6) and RAG1/2 involvement in t(8;22).
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary figure S6 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Cytogenetic of COH-DHL1 and COH-THL1 HGBCL-DH-BCL2(-BCL6) cell line models (A-D); In vivo secondary Ighv gene rearrangements in BCR-less murine lambda-MYC lymphomas (E-J)
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure S6 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
Cytogenetic of COH-DHL1 and COH-THL1 HGBCL-DH-BCL2(-BCL6) cell line models (A-D); In vivo secondary Ighv gene rearrangements in BCR-less murine lambda-MYC lymphomas (E-J)
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary figure S4 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
IGH and CD79B expression, complex formation and IGH isotype choice in DLBCL and HGBCL-DH-BCL2
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure S4 from B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements
IGH and CD79B expression, complex formation and IGH isotype choice in DLBCL and HGBCL-DH-BCL2